Improved communication with patients about cost, bleeding, and monitoring may increase compliance
Your search for apixaban returned 13 results
News
Lower Risk of CKD Stage Progression Found With Apixaban
Kidney injury may be less among patients with chronic kidney disease and atrial fibrillation taking apixaban versus warfarin for anticoagulation, new research suggests.
News
Rates of Adverse Events Lower With Apixaban for A-Fib in Older Adults
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels
News
Severe Abnormal Uterine Bleeding Risk With Anticoagulant Therapy Examined
Study findings revealed an increased risk of surgical intervention in women exposed to rivaroxaban.
News
Kidney Impairment Influences Safety, Efficacy of Anticoagulants for AFib
Investigators found an incremental increase in risks from oral anticoagulants as kidney function decreased, highlighting the need for more research to better understand bleeding risk and net benefit of treatment in the CKD population.
News
DOACs Appear Safer Than Warfarin Across Chronic Kidney Disease Stages
Although more research is needed, data suggest that the cardioprotective effect of direct oral anticoagulants may extend to patients with advanced CKD.
News
Non-Vitamin K Antagonist Oral Anticoagulants vs Warfarin in NVAF Patients
Findings may help with decision-making in this high-risk patient population.
News
Racial/Ethnic Disparities Seen in Anticoagulant Initiation for A-Fib
Disparities seen among VA patients both for initiating any anticoagulant therapy and for initiating direct-acting oral anticoagulant use
News
Effectiveness of Anticoagulants Compared for Valvular A-Fib
Risks for ischemic stroke or systemic embolism, major bleeding events lower with DOACs overall as a class versus warfarin
